Recent Activity

Loading...

OABI

OmniAb, Inc. · NASDAQ

Performance

-2.63%

1W

-7.68%

1M

-21.1%

3M

-0.0%

6M

-27.88%

YTD

+14.69%

1Y

Profile

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Investment Analysis Report: OABI

Overview:

OABI operates in the Commercial Services sector, specifically in Miscellaneous Commercial Services. The company has a market capitalization of $655,583,391. In this report, we will conduct a comprehensive analysis of OABI's financial statements to evaluate its valuation, financial health, earnings and r...

See more ...

Technical Analysis of OABI 2024-05-10

Overview:

In analyzing the technical indicators for the stock based on the last 5 days of data, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions ...

See more ...

Recent News & Updates